Tumor necrosis factor inhibitors in the management of juvenile idiopathic arthritis: An evidence-based review

Pediatric Drugs

Volumn 12, Issue 6, 2010, Pages 367-377

  Shenoi, Susan ^a   Wallace, Carol A ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Adalimumab, therapeutic use; Certolizumab pegol, therapeutic use; Etanercept, therapeutic use; Golimumab, therapeutic use; Infliximab, therapeutic use; Juvenile rheumatoid arthritis, treatment; Research and development; Tumour necrosis factor receptor antagonists, therapeutic use.

Indexed keywords

ADALIMUMAB; ANTIHISTAMINIC AGENT; CERTOLIZUMAB PEGOL; CORTICOSTEROID; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; METHOTREXATE; PARACETAMOL; PLACEBO; SIMPONI; TUMOR NECROSIS FACTOR INHIBITOR; UNCLASSIFIED DRUG;

CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; DEMYELINATION; DISEASE SEVERITY; DRUG COST; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG SAFETY; GASTROINTESTINAL SYMPTOM; HUMAN; INJECTION SITE REACTION; JUVENILE RHEUMATOID ARTHRITIS; LIVER FUNCTION TEST; LUPUS LIKE SYNDROME; MENTAL DISEASE; NONHODGKIN LYMPHOMA; OPTIC NEURITIS; PANCYTOPENIA; PERSONALITY DISORDER; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REVIEW; RISK FACTOR; SEIZURE; SIDE EFFECT; THYROID CARCINOMA; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; YOLK SAC TUMOR;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, JUVENILE RHEUMATOID; CHILD; EVIDENCE-BASED MEDICINE; HUMANS; IMMUNOGLOBULIN G; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77953480301     PISSN: 11745878     EISSN: 11792019     Source Type: Journal    
DOI: 10.2165/11532610-000000000-00000     Document Type: Review

References (125)

1. Carswell EA, Old LJ, Kassel RL, et al. An endotoxin-induced serum factor thatcausesnecrosisoftumors. Proc Natl Acad Sci USA 1975 Sep;72(9): 3666-70
2. Abbas AK, Lichtman AH. Cytokines. In: Cellular and molecular immunology. 5th ed. Philadelphia (PA): Elsevier Saunders, 2005: 243-74
3. Tracey D, Klareskog L, Sasso EH, et al. Tumor necrosis factor antagonist mechanisms ofaction: a comprehensive review. Pharmacol Ther 2008 Feb; 117 (2): 244-79
4. Grell M, Wajant H, Zimmermann G, et al. Thetype 1 receptor(CD120a)isthe high-affinity receptor for soluble tumor necrosis factor. Proc Natl Acad Sci USA 1998 Jan 20; 95 (2): 570-5
5. Grell M, Douni E, Wajant H, et al. The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor. Cell 1995 Dec 1; 83 (5): 793-802
6. Bazzoni F, Beutler B. The tumor necrosis factor ligand and receptor families. N Engl J Med 1996 Jun 27; 334 (26): 1717-25
7. Hehlgans T, Pfeffer K. The intriguing biology of the tumour necrosis factor/tumour necrosis factor receptor superfamily: players, rules and the games. Immunology 2005 May; 115 (1): 1-20
8. Kollias G. TNF pathophysiology in murine models ofchronic inflammation and autoimmunity. Semin Arthritis Rheum 2005 Apr; 34 (5 Suppl. 1): 3-6
9. Kollias G, Kontoyiannis D, Douni E, et al. The role of TNF/TNFRin organspecific and systemic autoimmunity: implications for the design ofoptimized 'anti-TNF' therapies. Curr Dir Autoimmun 2002; 5: 30-50
10. Grom AA, Murray KJ, Luyrink L, et al. Patterns of expression of tumor necrosis factor alpha, tumor necrosis factor beta, and their receptors in synovia of patients with juvenile rheumatoid arthritis and juvenile spondy-larthropathy. Arthritis Rheum 1996 Oct; 39 (10): 1703-10
11. Eberhard BA, Laxer RM, Andersson U, et al. Local synthesis ofboth macrophage and T cell cytokines by synovial fluid cells from children withjuvenile rheumatoid arthritis. Clin Exp Immunol 1994 May; 96 (2): 260-6
12. Yetgin S, Ozen S, Saatci U, et al. Evaluation oftumour necrosis factor alpha, interferon gamma and granulocyte-macrophage colony stimulating factor levels injuvenile chronic arthritis. Rheumatology (Oxford) 1999 May; 38 (5): 468-71
13. Saxne T, Palladino Jr MA, Heinegard D, et al. Detection of tumor necrosis factor alpha but not tumor necrosis factor beta in rheumatoid arthritis synovial fluid and serum. Arthritis Rheum 1988 Aug; 31 (8): 1041-5
14. Tak PP, Smeets TJ, Daha MR, et al. Analysis of the synovial cell infiltrate in early rheumatoid synovial tissue in relation to local disease activity. Arthritis Rheum 1997 Feb; 40 (2): 217-25
15. Ulfgren AK, Lindblad S, Klareskog L, et al. Detection ofcytokine producing cells in the synovial membrane from patients with rheumatoid arthritis. Ann Rheum Dis 1995 Aug; 54 (8): 654-61
16. Roux-Lombard P, Punzi L, Hasler F, et al. Soluble tumor necrosis factor receptors in human inflammatory synovial fluids. Arthritis Rheum 1993 Apr; 36 (4): 485-9
17. Mangge H, Kenzian H, Gallistl S, et al. Serum cytokines in juvenile rheumatoid arthritis: correlation with conventional inflammation parameters and clinical subtypes. Arthritis Rheum 1995 Feb; 38 (2): 211-20
18. Mangge H, Gallistl S, Schauenstein K. Long-term follow-up ofcytokines and soluble cytokine receptors in peripheral blood of patients with juvenile rheumatoid arthritis. J Interferon Cytokine Res 1999 Sep; 19 (9): 1005-10
19. Gattorno M, Picco P, Buoncompagni A, et al. Serum p55 and p75 tumour necrosis factor receptors as markers of disease activity in juvenile chronic arthritis. Ann Rheum Dis 1996 Apr; 55 (4): 243-7
20. Butler DM, Malfait AM, Mason LJ, et al. DBA/1 mice expressing the human TNF-alpha transgene develop a severe, erosive arthritis: characterization of thecytokinecascadeandcellularcomposition.JImmunol 1997Sep 15; 159(6): 2867-76
21. Klareskog L, McDevitt H. Rheumatoid arthritis and its animal models: the role of TNF-alpha and the possible absence of specific immune reactions. Curr Opin Immunol 1999 Dec; 11 (6): 657-62
22. Williams RO, Feldmann M, Maini RN. Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc Natl Acad Sci USA 1992 Oct 15; 89 (20): 9784-8
23. Enbrel [package insert]. Thousand Oaks (CA): Immunex Corporation, 1998-2009
24. Humira [package insert]. North Chicago (IL): Abbott Laboratories, 2009
25. Remicade [packageinsert]. Malvern (PA): Centocor Ortho Biotech, Inc. 2009
26. Simponi [package insert]. Horsham (PA): Centocor Ortho Biotech Inc., 2009
27. Cimzia [package insert]. Smyrna (GA): UCB, Inc. 2009
28. Lovell DJ, Giannini EH, Reiff A, et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med 2000 Mar 16; 342 (11): 763-9
29. Giannini EH, Ruperto N, Ravelli A, et al. Preliminary definition ofimprovement injuvenile arthritis. Arthritis Rheum 1997 Jul; 40 (7): 1202-9
30. Tzaribachev N, Kuemmerle-Deschner J, Eichner M, et al. Safety and efficacy of etanercept in children with juvenile idiopathic arthritis below the age of 4 years. Rheumatol Int 2008 Aug; 28 (10): 1031-4
31. ten Cate R, van Suijlekom-Smit LW, Brinkman DM, et al. Etanercept in four children with therapy-resistant systemicjuvenile idiopathic arthritis. Rheu-matology (Oxford) 2002 Feb; 41 (2): 228-9
32. Horneff G, Schmeling H, Biedermann T, et al. The German etanercept registry for treatment ofjuvenile idiopathic arthritis. Ann Rheum Dis 2004 Dec; 63 (12): 1638-44
33. Kietz DA, Pepmueller PH, Moore TL. Clinical response to etanercept in polyarticular coursejuvenile rheumatoid arthritis. J Rheumatol 2001 Feb; 28 (2): 360-2
34. Kietz DA, Pepmueller PH, Moore TL. Therapeutic use ofetanercept in polyarticular course juvenile idiopathic arthritis over a two year period. Ann Rheum Dis 2002 Feb; 61 (2): 171-3
35. Quartier P, Taupin P, Bourdeaut F, et al. Efficacy ofetanercept for the treatment ofjuvenile idiopathic arthritis according to the onset type. Arthritis Rheum 2003 Apr; 48 (4): 1093-101
36. Russo RA, Katsicas MM, Zelazko M. Etanercept in systemicjuvenile idiopathic arthritis. Clin Exp Rheumatol 2002 Sep-Oct; 20 (5): 723-6
37. Schmeling H, Mathony K, John V, et al. A combination of etanercept and methotrexate for the treatment of refractory juvenile idiopathic arthritis: a pilot study. Ann Rheum Dis 2001 Apr; 60 (4): 410-2
38. Kimura Y, Pinho P, Walco G, et al. Etanercept treatment in patients with refractory systemic onset juvenile rheumatoid arthritis. J Rheumatol 2005 May; 32 (5): 935-42
39. Prince FH, Twilt M, ten Cate R, et al. Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch national register. Ann Rheum Dis 2009 May; 68 (5): 635-41
40. De Benedetti F, Martini A. Is systemic juvenile rheumatoid arthritis an interleukin 6 mediated disease? J Rheumatol 1998 Feb; 25 (2): 203-7
41. de Benedetti F, Massa M, Robbioni P, et al. Correlation ofserum interleukin-6 levels with joint involvement and thrombocytosis in systemic juvenile rheumatoid arthritis. Arthritis Rheum 1991 Sep; 34 (9): 1158-63
42. Pignatti P, Vivarelli M, Meazza C, et al. Abnormal regulation of interleukin 6 in systemicjuvenile idiopathic arthritis. J Rheumatol 2001 Jul; 28 (7): 1670-6
43. Tse SM, Burgos-Vargas R, Laxer RM. Anti-tumor necrosis factor alpha blockade in the treatment ofjuvenile spondylarthropathy. Arthritis Rheum 2005 Jul; 52 (7): 2103-8
44. Tse SM, Laxer RM, Babyn PS, et al. Radiologic Improvement ofjuvenile idiopathic arthritis-enthesitis-related arthritis following anti-tumor necrosis factor-alpha blockade with etanercept. J Rheumatol 2006 Jun; 33 (6): 1186-8
45. Henrickson M, Reiff A. Prolonged efficacy ofetanercept in refractory enthesitis-related arthritis. J Rheumatol 2004 Oct; 31 (10): 2055-61
46. Homeff G, Burgos-Vargas R. TNF-alpha antagonists for the treatment ofjuvenile-onset spondyloarthritides. Clin Exp Rheumatol 2002 Nov-Dec; 20 (6 Suppl. 28): S137-42
47. Prince FH, Twilt M, Jansen-Wijngaarden NC, et al. Effectiveness of a once weekly double dose of etanercept in patients with juvenile idiopathic ar-thritis: a clinical study. Ann Rheum Dis 2007 May; 66 (5): 704-5
48. Prince FH, van Suijlekom-Smit LW. Initiating etanercept in a once weekly dose in children withjuvenile idiopathic arthritis. Rheumatol Int 2008 Feb; 28 (4): 8; author reply, 399
49. Horneff G, Ebert A, Fitter S, et al. Safety and efficacy of once weekly etanercept 0.8 mg/kg in a multicentre 12 week trial in active polyarticular course juvenileidiopathicarthritis. Rheumatology(Oxford)2009Aug; 48 (8): 916-9
50. Kuemmerle-Deschner JB, Horneff G. Safety and efficacy of once-weekly application of etanercept in children with juvenile idiopathic arthritis. Rheumatol Int 2007 Dec; 28 (2): 153-6
51. Yim DS, Zhou H, Buckwalter M, et al. Population pharmacokinetic analysis and simulation of the time-concentration profile of etanercept in pediatric patients withjuvenile rheumatoid arthritis. J Clin Pharmacol 2005 Mar; 45 (3): 246-56
52. Lovell DJ, Giannini EH, Reiff A, et al. Long-term efficacy and safety of etanercept in children with polyarticular-course juvenile rheumatoid ar-thritis: interim results from an ongoing multicenter, open-label, extended-treatment trial. Arthritis Rheum 2003 Jan; 48 (1): 218-26
53. Lovell DJ, Reiff A, Jones OY, et al. Long-term safety and efficacy ofetanercept in children with polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum 2006 Jun; 54 (6): 1987-94
54. Lovell DJ, Reiff A, Ilowite NT, et al. Safety and efficacy of up to eight years of continuous etanercept therapy in patients withjuvenile rheumatoid arthritis. Arthritis Rheum 2008 May; 58 (5): 1496-504
55. Giannini EH, Ilowite NT, Lovell DJ, et al. Long-term safety and effectiveness ofetanercept in children with selected categories ofjuvenile idiopathic ar-thritis. Arthritis Rheum 2009 Sep; 60 (9): 2794-804
56. Horneff G, De Bock F, Foeldvari I, et al. Safety and efficacy of combination ofetanercept and methotrexate compared to treatment with etanercept only in patients withjuvenile idiopathic arthritis (JIA): preliminary data from the German JIA Registry. Ann Rheum Dis 2009 Apr; 68 (4): 519-25
57. Halbig M, Horneff G. Improvement of functional ability in children with juvenile idiopathic arthritis by treatment with etanercept. Rheumatol Int. Epub 2009 May 16
58. Prince FH, Geerdink LM, Borsboom GJ, et al. Major improvements in health-related quality of life during the use of etanercept in patients with previously refractoryjuvenile idiopathic arthritis. Ann Rheum Dis 2010 Jan; 69 (1): 138-42
59. Nielsen S, Ruperto N, Gerloni V, et al. Preliminary evidence that etanercept may reduce radiographic progression in juvenile idiopathic arthritis. Clin Exp Rheumatol 2008 Jul-Aug; 26 (4): 688-92
60. Simonini G, Giani T, Stagi S, et al. Bone status over 1 yr of etanercept treatment injuvenile idiopathic arthritis. Rheumatology (Oxford) 2005 Jun; 44 (6): 777-80
61. Wallace CA, Ruperto N, Giannini E, Childhood Arthritis and Rheumatology Research Alliance, Pediatric Rheumatology International Trials Organiza-tion, Pediatric Rheumatology Collaborative Study Group. Preliminary cri-teria for clinical remission for select categories ofjuvenile idiopathic arthritis. J Rheumatol 2004 Nov; 31 (11): 2290-4
62. Prince FH, Twilt M, Simon SC, et al. When and how to stop etanercept after successful treatment of patients with juvenile idiopathic arthritis. Ann Rheum Dis 2009 Jul; 68 (7): 1228-9
63. Gerloni V, Pontikaki I, Gattinara M, et al. Efficacy ofrepeated intravenous infusions of an anti-tumor necrosis factor alpha monoclonal antibody, in-fliximab, in persistently active, refractoryjuvenile idiopathic arthritis: results of an open-label prospective study. Arthritis Rheum 2005 Feb; 52 (2): 548-53
64. Norambuena RX, Mallol J, Rios MG, et al. Therapeutic effects of the antitumor necrosis factor monoclonal antibody, infliximab, in four children with refractoryjuvenile idiopathic arthritis. Allergol Immunopathol (Madr) 2007 Mar-Apr; 35 (2): 52-6
65. Levalampi T, Honkanen V, Lahdenne P, et al. Effects ofinfliximab on cytokines, myeloperoxidase, and soluble adhesion molecules in patients withju-venile idiopathic arthritis. Scand J Rheumatol 2007 May-Jun; 36 (3): 189-93
66. Ruperto N, Lovell DJ, Cuttica R, et al. A randomized, placebo-controlled trial ofinfliximab plus methotrexate for the treatment ofpolyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum 2007 Sep; 56 (9): 3096-106
67. Ruperto N, Lovell DJ, Cuttica R, et al. Long-term efficacy and safety of infliximab plus methotrexate for the treatment ofpolyarticular coursejuvenile rheumatoid arthritis: findings from an open-label treatment extension. Ann Rheum Dis 2010 Apr; 69 (4): 718-22
68. Gerloni V, Pontikaki I, Gattinara M, et al. Focus on adverse events oftumour necrosis factor alpha blockade in juvenile idiopathic arthritis in an open monocentric long-term prospective study of 163 patients. Ann Rheum Dis 2008 Aug; 67 (8): 1145-52
69. Elliott MJ, Woo P, Charles P, et al. Suppression offever and the acute-phase response in a patient with juvenile chronic arthritis treated with monoclonal antibody to tumour necrosis factor-alpha (cA2). Br J Rheumatol 1997 May; 36 (5): 589-93
70. Billiau AD, Cornillie F, Wouters C. Infliximab for systemic onset juvenile idiopathic arthritis: experience in 3 children. J Rheumatol 2002 May; 29 (5): 1111-4
71. Katsicas MM, Russo RA. Use ofinfliximab in patients with systemicjuvenile idiopathic arthritis refractory to etanercept. Clin Exp Rheumatol 2005 Jul-Aug; 23 (4): 545-8
72. Burgos-Vargas R. A case of childhood-onset ankylosing spondylitis: diagnosis and treatment. Nat Clin Pract Rheumatol 2009 Jan; 5 (1): 52-7
73. D'Agostino MA, Breban M, Said-Nahal R, et al. Refractory inflammatory heel pain in spondylarthropathy: a significant response to infliximab documented by ultrasound. Arthritis Rheum 2002 Mar; 46 (3): 840-1; author reply, 841-3
74. Schmeling H, Horneff G. Infliximab in two patients withjuvenile ankylosing spondylitis. Rheumatol Int 2004 May; 24 (3): 173-6
75. Nerome Y, Imanaka H, Nonaka Y, et al. Switching the therapy from etanercept to infliximab in a child with rheumatoid factor positive polyarticular juvenile idiopathic arthritis. Mod Rheumatol 2007; 17 (6): 526-8
76. Favalli EG, Arreghini M, Arnoldi C, et al. Anti-tumor necrosis factor alpha switching in rheumatoid arthritis and juvenile chronic arthritis. Arthritis Rheum 2004 Apr 15; 51 (2): 301-2
77. Lahdenne P, Vahasalo P, Honkanen V. Infliximab or etanercept in the treatment of children with refractory juvenile idiopathic arthritis: an open label study. Ann Rheum Dis 2003 Mar; 62 (3): 245-7
78. Lovell DJ, Ruperto N, Goodman S, et al. Adalimumab with or without methotrexate injuvenile rheumatoid arthritis. N Engl J Med 2008 Aug 21; 359 (8): 810-20
79. de Vries MK, van der Horst-Bruinsma IE, Wolbink GJ. Adalimumab in juvenile rheumatoid arthritis. N Engl J Med 2008 Dec 4; 359 (23): 2496; author reply, 2496-7
80. Abbott. Study of the human anti-tumor necrosis factor (TNF) monoclonal antibody adalimumab in children with polyarticular juvenile idiopathic ar-thritis(JIA) [Clinical Trials.govidentifier NCT00048542]. US National Insti-tutes of Health, Clinical Trials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2010 Aug 2]
81. Katsicas MM, Russo RA. Use ofadalimumab in patients withjuvenile idiopathic arthritis refractory to etanercept and/or infliximab. Clin Rheumatol 2009 Aug; 28 (8): 985-8
82. Olivieri I, Scarano E, Gigliotti P, et al. Successful treatment ofjuvenile-onset HLA-B27-associated severe and refractory heel thesitis with adalimumab documented by magnetic resonance imaging. Rheumatology (Oxford) 2006 Oct; 45 (10): 1315-7
83. Abbott. Active juvenile idiopathic arthritis (JIA) compassionate use [Clinical Trials.gov identifier NCT00775437]. US National Institutes ofHealth, Clinical Trials.gov [online]. Available from URL: http://www.clinicaltrials. gov [Accessed 2010 Aug 2]
84. Abbott. Juvenile idiopathic arthritis (JIA) registry (STRIVE) [Clinical Trials. gov identifier NCT00783510]. US National Institutes ofHealth, Clinical-Trials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2010 Aug 2]
85. Abbott. Safety, efficacy, and pharmacokinetics ofadalimumab in Japanese children with juvenile rheumatoid arthritis [Clinical Trials.gov identifier NCT00690573]. US National Institutes ofHealth, Clinical Trials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2010 Aug 2]
86. Keystone E, Heijde D, Mason Jr D, et al. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in ac-tive rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 2008 Nov; 58 (11): 3319-29
87. Choy EH, Hazleman B, Smith M, et al. Efficacy of a novel PEGylated humanized anti-TNF fragment (CDP870) in patients with rheumatoid ar-thritis: a phase II double-blinded, randomized, dose-escalating trial. Rheu-matology (Oxford) 2002 Oct; 41 (10): 1133-7
88. Fleischmann R, Vencovsky J, van Vollenhoven RF, et al. Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheu-matoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study. Ann Rheum Dis 2009 Jun; 68 (6): 805-11
89. Smolen J, Landewe RB, Mease P, et al. Efficacy and safety ofcertolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study: a randomised controlled trial. Ann Rheum Dis 2009 Jun; 68 (6): 797-804
90. Barnes T, Moots R. Targeting nanomedicines in the treatment of rheumatoid arthritis: focus on certolizumab pegol. Int J Nanomedicine 2007; 2 (1): 3-7
91. Emery P, Fleischmann RM, Moreland LW, et al. Golimumab, a human antitumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis. Arthritis Rheum 2009 Aug; 60 (8): 2272-83
92. Keystone EC, Genovese MC, Klareskog L, et al. Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study. Ann Rheum Dis 2009 Jun; 68 (6): 789-96
93. Smolen JS, Kay J, Doyle MK, et al. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha in-hibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. Lancet 2009 Jul 18; 374 (9685): 210-21
94. Kay J, Matteson EL, Dasgupta B, et al. Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging study. Arthritis Rheum 2008 Apr; 58 (4): 964-75
95. Zhou H, Jang H, Fleischmann RM, et al. Pharmacokinetics and safety of golimumab, a fully human anti-TNF-alpha monoclonal antibody, in sub-jects with rheumatoid arthritis. J Clin Pharmacol 2007 Mar; 47 (3): 383-96
96. Simard JF, Neovius M, Hagelberg S, et al. Juvenile idiopathic arthritis and risk of cancer: a nationwide cohort study. EULAR 2010 [abstract]. Ann Rheum Dis 2010; 69 Suppl. 3: 81
97. Harrison M, Nordstrom B, Gu Y, et al. Riskofmalignancyinbiologics-naive juvenilearthritispatients. EULAR2010 [abstract].Ann Rheum Dis2010; 69 Suppl. 3: 631
98. Questions and answers-TNF blockers 8/25/2009 [online]. Available from URL: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInfor mationforPatientsandProviders/DrugSafetyInformationforHeathcareProfes sionals/ucm180694.htm [Accessed 2009 Sep 3]
99. Diak P, Siegel J, Grenade LL, et al. Tumor necrosis factor a blockers and malignancy in children. Arthritis Rheum 2010 Aug; 62 (8): 2517-24
100. McCroskery P, Wallace CA, Lovell DJ, et al. Summary ofworldwide pediatric malignancies reported after exposure to etanercept. Pediatr Rheumatol Online J 2010 Jun 14; 8: 18
101. Yokota S, Imagawa T, Mori M, et al. Efficacy and safety oftocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet 2008 Mar 22; 371 (9617): 998-1006
102. Yokota S, Miyamae T, Imagawa T, et al. Clinical study of tocilizumab in children with systemic-onset juvenile idiopathic arthritis. Clin Rev Allergy Immunol 2005 Jun; 28 (3): 231-8
103. Verbsky JW, White AJ. Effective use of the recombinant interleukin 1 receptor antagonist anakinra in therapy resistant systemic onset juvenile rheu-matoid arthritis. J Rheumatol 2004 Oct; 31 (10): 2071-5
104. Lequerre T, Quartier P, Rosellini D, et al. Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onsetjuvenile idiopathic ar-thritis or adult onset Still disease: preliminary experience in France. Ann Rheum Dis 2008 Mar; 67 (3): 302-8
105. Sulpice M, Deslandre CJ, Quartier P. Efficacy and safety of TNFalpha antagonist therapy in patients withjuvenile spondyloarthropathies. Joint Bone Spine 2009 Jan; 76 (1): 24-7
106. Foeldvari I, Nielsen S, Kummerle-Deschner J, et al. Tumor necrosis factoralpha blocker in treatment ofjuvenile idiopathic arthritis-associated uveitis refractory to second-line agents: results of a multinational survey. J Rheu-matol 2007 May; 34 (5): 1146-50
107. Richards JC, Tay-Kearney ML, Murray K, et al. Infliximab forjuvenile idiopathic arthritis-associated uveitis. Clin Experiment Ophthalmol 2005 Oct; 33 (5): 461-8
108. Reiff A, Takei S, Sadeghi S, et al. Etanercept therapy in children with treatment-resistant uveitis. Arthritis Rheum 2001 Jun; 44 (6): 1411-5
109. Reiff A. Long-term outcome ofetanercept therapy in children with treatmentrefractory uveitis. Arthritis Rheum 2003 Jul; 48 (7): 2079-80
110. Tynjala P, Lindahl P, Honkanen V, et al. Infliximab and etanercept in the treatment of chronic uveitis associated with refractory juvenile idiopathic arthritis. Ann Rheum Dis 2007 Apr; 66 (4): 548-50
111. Tynjala P, Kotaniemi K, Lindahl P, et al. Adalimumab in juvenile idiopathic arthritis-associated chronic anterior uveitis. Rheumatology (Oxford) 2008 Mar; 47 (3): 339-44
112. Vazquez-Cobian LB, Flynn T, Lehman TJ. Adalimumab therapy for childhood uveitis. J Pediatr 2006 Oct; 149 (4): 572-5
113. Biester S, Deuter C, Michels H, et al. Adalimumab in the therapy of uveitis in childhood. Br J Ophthalmol 2007 Mar; 91 (3): 319-24
114. Mangge H, Heinzl B, Grubbauer HM, et al. Therapeutic experience with infliximab in a patient with polyarticular juvenile idiopathic arthritis and uveitis. Rheumatol Int 2003 Sep; 23 (5): 258-61
115. Smith JA, Thompson DJ, Whitcup SM, et al. Arandomized,placebo-controlled, double-masked clinical trial ofetanercept for the treatment of uveitis associated withjuvenile idiopathic arthritis. Arthritis Rheum 2005 Feb 15; 53 (1): 18-23
116. Saurenmann RK, Levin AV, Feldman BM, et al. Risk ofnew-onset uveitis in patients withjuvenile idiopathic arthritis treated with anti-TNFalpha agents. J Pediatr 2006 Dec; 149 (6): 833-6
117. Saurenmann RK, Levin AV, Rose JB, et al. Tumour necrosis factor alpha inhibitors in the treatment of childhood uveitis. Rheumatology (Oxford) 2006 Aug; 45 (8): 982-9
118. Schmeling H, Horneff G. Etanercept and uveitis in patients with juvenile idiopathic arthritis. Rheumatology (Oxford) 2005 Aug; 44 (8): 1008-11
119. Rajaraman RT, Kimura Y, Li S, et al. Retrospective case review ofpediatric patients with uveitis treated with infliximab. Ophthalmology 2006 Feb; 113 (2): 308-14
120. Theodossiadis PG, Markomichelakis NN, Sfikakis PP. Tumor necrosis factor antagonists: preliminary evidence for an emerging approach in the treatment ofocular inflammation. Retina 2007 Apr-May; 27 (4): 399-413
121. Brik R, Gepstein V, Shahar E, et al. Tumor necrosis factor blockade in the management of children with orphan diseases. Clin Rheumatol 2007 Oct; 26 (10): 1783-5
122. Haapasaari J, Kautiainen H, Hannula S, et al. Good results from combining etanercept to prevailing DMARD therapy in refractory juvenile idiopathic arthritis. Clin Exp Rheumatol 2002 Nov-Dec; 20 (6): 867-70
123. Bellofiore B, Matarese A, Balato N, et al. Prevention of tuberculosis in patients taking tumor necrosis factor-alpha blockers. J Rheumatol Suppl 2009 Aug; 83: 76-7
124. Minden K, Kiessling U, Listing J, et al. Prognosis ofpatients withjuvenile chronic arthritis andjuvenile spondyloarthropathy. J Rheumatol 2000 Sep; 27 (9): 2256-63
125. National Institute of Arthritis and Musculoskelet al and Skin Diseases (NIAMS). Trial of early aggressive drug therapy in juvenile idiopathic arthritis [Clinical-Trials.gov identifier NCT00443430]. US National Institutes ofHealth, Clinical-Trials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2010 Aug 2]